SRR1419714
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.505
- APICAL_SURFACE+0.238
- SPERMATOGENESIS+0.180
- PANCREAS_BETA_CELLS+0.177
- COAGULATION+0.174
- HEDGEHOG_SIGNALING+0.128
- MYOGENESIS+0.128
- INFLAMMATORY_RESPONSE+0.052
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.042
- ESTROGEN_RESPONSE_LATE+0.028
Top 10 suppressed
- MYC_TARGETS_V1-0.663
- MTORC1_SIGNALING-0.576
- OXIDATIVE_PHOSPHORYLATION-0.574
- PROTEIN_SECRETION-0.559
- UNFOLDED_PROTEIN_RESPONSE-0.546
- DNA_REPAIR-0.530
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.511
- MYC_TARGETS_V2-0.474
- E2F_TARGETS-0.461
- G2M_CHECKPOINT-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1474886 | GTEX | — | 0.968 |
| 2 | MDT-AP-1143 | Med | Medulloblastoma | 0.967 |
| 3 | SRR1348861 | GTEX | — | 0.965 |
| 4 | BS_9F09XV62 | low-grade glioma | — | 0.963 |
| 5 | BS_23W9EPFE | Ganglioglioma | — | 0.962 |
| 6 | BS_TCGEZJ5F | EPN | Supratentorial EPN | 0.962 |
| 7 | SRR1500405 | GTEX | — | 0.961 |
| 8 | SRR1336006 | GTEX | — | 0.961 |
| 9 | SRR1451964 | GTEX | — | 0.959 |
| 10 | SRR1340301 | GTEX | — | 0.959 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.505 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.238 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.177 | Cobimetinib | — uncovered |
| COAGULATION | 0.174 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.128 | Inavolisib | — uncovered |
| MYOGENESIS | 0.128 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.052 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.042 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.028 | Idelalisib | — uncovered |